 |
      
|
|
|
|
|
|||||
|
|
July 16, 2004
Neurochem to hold conference call and webcast on interim Alzhemed™ results unveiled at
9th International Conference on Alzheimer's Disease and Related Disorders. Live Web Conference
To participate in the conference call and webcast, please dial 1 877-888-4210 approximately 10
minutes prior to the start of the call AND access Neurochem's website at www.neurochem.com. The
dial-in number will allow participants to listen and ask questions, while the webcast will provide
a visual presentation. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's pipeline of proprietary, disease-modifying, oral products
addresses critical unmet medical needs. Fibrillex™, designated as an orphan drug and as a
Fast Track Product candidate, is also part of a Continuous Marketing Applications Pilot 2 program
and is currently in a Phase II/III clinical trial for the treatment of AA Amyloidosis.
Alzhemed™, for the treatment of Alzheimer's disease, is in a Phase III clinical trial and
Cerebril™, for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy,
has completed a Phase II clinical trial.
Certain statements contained in this news release, other than statements of fact that are independently
verifiable at the date hereof, may constitute forward-looking statements. Such statements, based
as they are on the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include
but are not limited to: the impact of general economic conditions, general conditions in the
pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which
Neurochem does business, stock market volatility, fluctuations in costs, and changes to the
competitive environment due to consolidation as well as other risks included in public filings
of Neurochem. Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. The reader should not place undue reliance
on the forward-looking statements included in this news release. These statements speak only as
of the date made and Neurochem is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
